MEPs back 120bn budget for Horizon Europe
The European Parliament has voted to add 36.5bn to the budget of Horizon Europe (94.1bn, in 2018 prices) proposed by the European Commission to foster research and innovation.
New cheap CRS-blockers at the horizon
Cancer immunotherapies are often associated with severe cytokine release syndrome (CRS) that can be managed with IL-6R-blockers. US oncologists now report that an FDA-approved hypertension drug did the same job as Roche’s anti-IL-6R blocker tocolizumab.
Oxford BioTherapeutics in $450 deal with Wuxi Biologics
Immuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics WuXiBody platform.
Diabetes doubles risk for heart failure
An analysis of health records of the whole Scottish population aged ?30 years revealed that people with diabetes have an increased risk for heart failure.
AZ checkpoint blocker combo fails in head and neck cancer
British drugmaker AstraZeneca (AZ) has missed another opportunity to secure a share in the lucrative immunoncology market: a Phase III trial combining durvalumab with tremelimumab missed the survival endpoint.
XyloCor Therapeutics bags US$17m in Series A financing
LSP and Sofinnova Ventures co-led the financing of the Amsterdam-based gene therapy specialist XyloCor Therapeutics.
BioFIT: innovation and investors
For two days, Lille was the place to be for partnering in early stage innovation. On December 5th, Europe’s leading tech transfer event BioFIT wrapped up, recording a record number of participants.
Uncommon mutations affect breast cancer prognosis
Uncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications.
Argenx in US$1.6bn deal with J&J affiliate Janssen
Janssen affiliate Cilag GmbH International has licenced argenx anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.
Driver of GVHD after blood stem cell transplantation identified
Swiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.